Cognitive Dysfunction ( MMSE < 24 )TDCSCOGSCDTRIANCT07531888
Effects of tDCS on Cognitive Function in Older Adults With Subjective Cognitive Decline: Randomized Sham-Controlled Trial
A study testing Transcranial Direct Current Stimulation in people with Cognitive Dysfunction ( MMSE < 24 ), run by Universidad Autónoma del Estado de Hidalgo at 1 site in Mexico.
Trial summary
This randomized, double-blind, sham-controlled clinical trial evaluates the effects of transcranial direct current stimulation (tDCS) using the Sooma Oy device on cognitive function in older adults with Subjective Cognitive Decline (SCD). Read more about this study
- Who is it for?
- Ages 60 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Cognitive Dysfunction ( MMSE < 24 )
- What is being tested?
- Transcranial Direct Current Stimulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteMexico
- Study dates
- 17 Apr 2026to 30 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Right-handed (for MRI purposes)
- Age 60 to 75 years
- 6 years or more of schooling
- Proficiency in Spanish
- Amnestic Mild Cognitive Impairment established by clinical examination
- Adequate visual and auditory acuity to perform neuropsychological tests and undergo cognitive rehabilitation
Show all 9Show fewer
- If receiving psychotropic medication, to have started it at least 12 weeks prior to the start of the study, remain at stable doses, or have discontinued it for at least 4 weeks
- Good general health without medical or psychiatric illnesses that would interfere with the study
- An informant capable of responding to clinimetric assessments throughout the study and willing to accompany the patient for at least 10 hours per week
Who cannot join
- 1. Any neurological disease other than Alzheimer's disease that raises suspicion of cognitive impairment, such as Parkinson's disease, multiple infarct dementia, Huntington's disease, hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or a history of traumatic brain injury with loss of consciousness.
- 2. Participants with a history of severe psychiatric disorders according to the DSM-5 (bipolar disorder, schizophrenia, chronic depression) or with psychotic features, agitation, or behavioral problems in the last three months that could lead to difficulties in complying with the protocol.
- 3. History of psychoactive substance abuse and current alcohol consumption with a pattern of abuse or dependence in the last two years.
- 4. Participants with abnormalities on a conventional electroencephalogram (paroxysmal phenomena identified by a neurophysiologist). 5. Participants with pacemakers, intracranial metallic objects or a history of brain surgery, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.
- 5. Participants with pacemakers, intracranial metallic objects or a history of brain surgery, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body.
- 6. Participation in clinical studies with neuropsychological measures taken more than once a year.
- 7. Having received prior treatment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Mexico1 site
Universidad Autonoma del Estado de Hidalgo
Pachuca, Hidalgo, 42082
About this study
Official title: Effects of Transcranial Direct Current Stimulation (tDCS) on Cognitive Function in Older Adults With Subjective Cognitive Decline: A Randomized, Double-Blind, Sham-Controlled Trial.
This randomized, double-blind, sham-controlled clinical trial evaluates the effects of transcranial direct current stimulation (tDCS) using the Sooma Oy device on cognitive function in older adults with Subjective Cognitive Decline (SCD). The study investigates changes in memory, executive function, attention, and global cognition after a structured intervention consisting of 22 intensive sessions and 8 maintenance sessions. Assessments occur at baseline, Week 4, Week 8, and Week 12.
Read the detailed description
This study uses the Sooma tDCS system (Sooma Oy, Finland) to deliver a current of 2 mA for 30 minutes per session. The anode is positioned over F3 (left dorsolateral prefrontal cortex) and the cathode over F4 (right dorsolateral prefrontal cortex), according to the international 10-20 system. Participants receive 22 intensive sessions (five days per week) followed by 8 weekly maintenance sessions. The sham condition mimics the stimulation procedure through a 30-second ramp-up and ramp-down period without sustained active stimulation.
Primary and secondary outcomes focus on changes in cognitive function, assessed using validated neuropsychological instruments.
In addition, the study includes the analysis of molecular biomarkers associated with calcium (Ca²⁺) homeostasis, as age-related changes disrupt multiple electrophysiological processes within the hippocampus. These alterations have been proposed as potential biomarkers of brain aging and are closely linked to cognitive decline. Biological samples will be obtained through buccal swabs using sterile cotton applicators from participating older adults. Total RNA will then be extracted using the TRIzol method, followed by the design of specific primer oligonucleotides and amplification using a commercial RT-PCR kit.
This clinical trial aims to generate evidence on the therapeutic utility of tDCS in individuals with Subjective Cognitive Decline, supporting early intervention strategies and contributing to the identification of molecular correlates associated with cognitive changes.
- Conditions
- Cognitive Dysfunction ( MMSE < 24 )
- Being tested
- Transcranial Direct Current Stimulation
- Keywords
- tDCS Randomized Controlled Trial Sham-Controlled Cognitive Intervention Aging Brain
- Medical subject headings
- Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transcranial Direct Current StimulationDevice
Transcranial direct current stimulation (tDCS) is administered using the Sooma tDCS system (Sooma Oy, Finland). Active stimulation consists of delivering a constant current of 2 mA for 30 minutes per session, with the anode positioned over F3 (left dorsolateral prefrontal cortex) and the cathode over F4 (right dorsolateral prefrontal cortex) according to the international 10-20 EEG system. Participants receive 22 intensive sessions delivered five days per week, followed by 8 weekly maintenance sessions.
For the sham condition, the same electrode placement and session duration are used; however, stimulation is applied only during a 30-second ramp-up and ramp-down period, with no sustained current delivered for the remainder of the session. This procedure is designed to maintain participant and assessor blinding.
| Study group | Role | What they receive |
|---|---|---|
| Treatment | Experimental | Participants assigned to the experimental group will receive active transcranial direct current stimulation (tDCS) using the Sooma tDCS system (Sooma Oy, Finland). The intervention consists of delivering a 2 mA current for 30 minutes per session, with the anode positioned over F3 (left dorsolateral prefrontal cortex) and the cathode over F4 (right dorsolateral prefrontal cortex), according to the international 10-20 system. The stimulation protocol includes 22 intensive sessions administered five days per week, followed by 8 weekly maintenance sessions. All sessions will be conducted under established safety and monitoring guidelines for non-invasive brain stimulation. Receives: Device: Transcranial Direct Current Stimulation |
| Sham | Placebo comparator | Participants assigned to the control (sham/placebo) group will receive sham transcranial direct current stimulation (tDCS) using the Sooma tDCS system (Sooma Oy, Finland). The procedure will replicate the experimental group conditions, including electrode placement over F3 (left dorsolateral prefrontal cortex) and F4 (right dorsolateral prefrontal cortex), as well as identical session duration. However, active stimulation will be delivered only during an initial 30-second ramp-up and ramp-down period, with no sustained current administered for the remainder of the session. This approach ensures proper blinding of both participants and outcome assessors. Receives: Device: Transcranial Direct Current Stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Global cognitive function
Executive Function, Working Memory, Verbal Fluency, Episodic Memory, Planning, and Global Cognition Executive function will be assessed using the Five Digits Test (time/errors; lower = better; no fixed range). Verbal working memory will be measured with Digit Span (approx. 0-16 forward, 0-14 backward; higher = better) and visuospatial working memory with the Corsi Block-Tapping Test (span 2-9; higher = better). Verbal fluency will be assessed using phonemic fluency (letter F; no fixed range; higher = better). Episodic memory will be measured with the Hopkins Verbal Learning Test-Revised (HVLT-R; immediate recall 0-36, delayed recall 0-12; higher = better). Planning ability will be evaluated with the Tower of London (moves/time; lower = better; no fixed range). Global cognition will be assessed using the Montreal Cognitive Assessment (MoCA; 0-30; higher = better).
[Time Frame: Baseline, Week 5, Week 8, and Week 12]
Measured: Participants will undergo a 1-week baseline assessment, followed by a 5-week intensive intervention phase. A post-intervention assessment will be conducted at Week 6. Follow-up assessments will be performed at Weeks 10, 14, and 18. The total study durati
Secondary outcomes (1)
Calcium-related molecular biomarkers (STIM and ORAI gene expression)
Gene expression levels of STIM and ORAI will be measured from buccal swab samples using RT-PCR. Relative gene expression will be quantified (fold change). Changes in expression levels will be analyzed between groups, where increased or decreased expression reflects modulation of calcium-related pathways.
[Time Frame: Baseline, Week 5, Week 8, and Week 12]
Measured: Baseline (pre-intervention), post-intervention (after completion of the intensive phase, Week 5), and follow-up assessments (Weeks 8 and 12)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2026
- Study start17 Apr 2026 (estimated)
- Primary completionNov 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Cognitive Dysfunction ( MMSE < 24 )Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study is a randomized clinical trial with two parallel groups, using a double-blind design, in which an active treatment group receiving transcranial direct current stimulation (tDCS) is compared with a sham (placebo) control group. Participants are randomly assigned to each group, and blinding is maintained for both participants and outcome assessors. This design allows for rigorous control of bias and a valid evaluation of treatment efficacy.
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidad Autónoma del Estado de Hidalgo
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, José Jesús Serrano Ruíz, Universidad Autónoma del Estado de Hidalgo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07531888
- Sponsor's protocol ID
- UniversidadAEH
- Acronym
- TDCSCOGSCDTRIA
- Status last verified
- Apr 2026
- First submitted
- 12 Feb 2026
- Last updated
- 15 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: This study represents the first time the research team has registered a clinical trial; therefore, the process of defining and classifying outcome measures has been carried out with particular care to ensure methodological clarity and coherence. In addition to clinical and neuropsychological outcomes, the study includes an exploratory measurement of molecular biomarkers related to calcium (Ca²⁺) homeostasis, as age-related changes disrupt multiple electrophysiological processes, particularly at the hippocampal level. These alterations have been proposed as potential biomarkers of cognitive decline. The inclusion of this measurement is complementary and exploratory in nature, and its purpose is to provide additional information that allows for a more comprehensive interpretation of the cognitive changes observed following transcranial direct current stimulation (tDCS). The collection of biological samples through buccal swabbing constitutes a non-invasive, safe, and appropriate proced
Publications
Dedoncker J, Brunoni AR, Baeken C, Vanderhasselt MA. The effect of the interval-between-sessions on prefrontal transcranial direct current stimulation (tDCS) on cognitive outcomes: a systematic review and meta-analysis. J Neural Transm (Vienna). 2016 Oct;123(10):1159-72. doi: 10.1007/s00702-016-1558-x. Epub 2016 May 4.
PubMed 27145765Galli G, Vadillo MA, Sirota M, Feurra M, Medvedeva A. A systematic review and meta-analysis of the effects of transcranial direct current stimulation (tDCS) on episodic memory. Brain Stimul. 2019 Mar-Apr;12(2):231-241. doi: 10.1016/j.brs.2018.11.008. Epub 2018 Nov 17.
PubMed 30503376Huo L, Zhu X, Zheng Z, Ma J, Ma Z, Gui W, Li J. Effects of Transcranial Direct Current Stimulation on Episodic Memory in Older Adults: A Meta-analysis. J Gerontol B Psychol Sci Soc Sci. 2021 Mar 14;76(4):692-702. doi: 10.1093/geronb/gbz130.
PubMed 31782505Manenti R, Sandrini M, Gobbi E, Binetti G, Cotelli M. Effects of Transcranial Direct Current Stimulation on Episodic Memory in Amnestic Mild Cognitive Impairment: A Pilot Study. J Gerontol B Psychol Sci Soc Sci. 2020 Aug 13;75(7):1403-1413. doi: 10.1093/geronb/gby134.
PubMed 30395314
Study at a glance
From the registry record, last updated by the sponsor on 15 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Transcranial Direct Current Stimulation (tDCS) on Cognitive Function in Older Adults With Subjective Cognitive Decline: A Randomized, Double-Blind, Sham-Controlled Trial.
- ClinicalTrials.gov ID
- NCT07531888
- Acronym / sponsor ID
- TDCSCOGSCDTRIA / UniversidadAEH
- Conditions
- Cognitive Dysfunction ( MMSE < 24 )
- Keywords
- tDCS Randomized Controlled Trial Sham-Controlled Cognitive Intervention Aging Brain
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Universidad Autónoma del Estado de HidalgoUniversity, hospital or other
- Study start
- 17 Apr 2026 (estimated)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 15 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized, double-blind, sham-controlled clinical trial evaluates the effects of transcranial direct current stimulation (tDCS) using the Sooma Oy device on cognitive function in older adults with Subjective Cognitive Decline (SCD). The study investigates changes in memory, executive function, attention, and global cognition after a structured intervention consisting of 22 intensive sessions and 8 maintenance sessions. Assessments occur at baseline, Week 4, Week 8, and Week 12.
Detailed description
This study uses the Sooma tDCS system (Sooma Oy, Finland) to deliver a current of 2 mA for 30 minutes per session. The anode is positioned over F3 (left dorsolateral prefrontal cortex) and the cathode over F4 (right dorsolateral prefrontal cortex), according to the international 10-20 system. Participants receive 22 intensive sessions (five days per week) followed by 8 weekly maintenance sessions. The sham condition mimics the stimulation procedure through a 30-second ramp-up and ramp-down period without sustained active stimulation.
Primary and secondary outcomes focus on changes in cognitive function, assessed using validated neuropsychological instruments.
In addition, the study includes the analysis of molecular biomarkers associated with calcium (Ca²⁺) homeostasis, as age-related changes disrupt multiple electrophysiological processes within the hippocampus. These alterations have been proposed as potential biomarkers of brain aging and are closely linked to cognitive decline. Biological samples will be obtained through buccal swabs using sterile cotton applicators from participating older adults. Total RNA will then be extracted using the TRIzol method, followed by the design of specific primer oligonucleotides and amplification using a commercial RT-PCR kit.
This clinical trial aims to generate evidence on the therapeutic utility of tDCS in individuals with Subjective Cognitive Decline, supporting early intervention strategies and contributing to the identification of molecular correlates associated with cognitive changes.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
- Model description
- This study is a randomized clinical trial with two parallel groups, using a double-blind design, in which an active treatment group receiving transcranial direct current stimulation (tDCS) is compared with a sham (placebo) control group. Participants are randomly assigned to each group, and blinding is maintained for both participants and outcome assessors. This design allows for rigorous control of bias and a valid evaluation of treatment efficacy.
| Arm | Type | Receives |
|---|---|---|
| Treatment | Experimental | Device: Transcranial Direct Current StimulationParticipants assigned to the experimental group will receive active transcranial direct current stimulation (tDCS) using the Sooma tDCS system (Sooma Oy, Finland). The intervention consists of delivering a 2 mA current for 30 minutes per session, with the anode positioned over F3 (left dorsolateral prefrontal cortex) and the cathode over F4 (right dorsolateral prefrontal cortex), according to the international 10-20 system. The stimulation protocol includes 22 intensive sessions administered five days per week, followed by 8 weekly maintenance sessions. All sessions will be conducted under established safety and monitoring guidelines for non-invasive brain stimulation. |
| Sham | Placebo comparator | Device: Transcranial Direct Current StimulationParticipants assigned to the control (sham/placebo) group will receive sham transcranial direct current stimulation (tDCS) using the Sooma tDCS system (Sooma Oy, Finland). The procedure will replicate the experimental group conditions, including electrode placement over F3 (left dorsolateral prefrontal cortex) and F4 (right dorsolateral prefrontal cortex), as well as identical session duration. However, active stimulation will be delivered only during an initial 30-second ramp-up and ramp-down period, with no sustained current administered for the remainder of the session. This approach ensures proper blinding of both participants and outcome assessors. |
Who may qualify
- Ages
- 60 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Right-handed (for MRI purposes)
- Age 60 to 75 years
- 6 years or more of schooling
- Proficiency in Spanish
- Amnestic Mild Cognitive Impairment established by clinical examination
Key exclusion criteria (7 listed)
- 1. Any neurological disease other than Alzheimer's disease that raises suspicion of cognitive impairment, such as Parkinson's disease, multiple infarct dementia, Huntington's disease, hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or a history of traumatic brain injury with loss of consciousness.
- 2. Participants with a history of severe psychiatric disorders according to the DSM-5 (bipolar disorder, schizophrenia, chronic depression) or with psychotic features, agitation, or behavioral problems in the last three months that could lead to difficulties in complying with the protocol.
- 3. History of psychoactive substance abuse and current alcohol consumption with a pattern of abuse or dependence in the last two years.
- 4. Participants with abnormalities on a conventional electroencephalogram (paroxysmal phenomena identified by a neurophysiologist). 5. Participants with pacemakers, intracranial metallic objects or a history of brain surgery, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.
- 5. Participants with pacemakers, intracranial metallic objects or a history of brain surgery, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transcranial Direct Current StimulationTranscranial direct current stimulation (tDCS) is administered using the Sooma tDCS system (Sooma Oy, Finland). Active stimulation consists of delivering a constant current of 2 mA for 30 minutes per session, with the anode positioned over F3 (left dorsolateral prefrontal cortex) and the cathode over F4 (right dorsolateral prefrontal cortex) according to the international 10-20 EEG system. Participants receive 22 intensive sessions delivered five days per week, followed by 8 weekly maintenance sessions. For the sham condition, the same electrode placement and session duration are used; however, stimulation is applied only during a 30-second ramp-up and ramp-down period, with no sustained current delivered for the remainder of the session. This procedure is designed to maintain participant and assessor blinding. | Device | Sham, Treatment |
Primary outcome
Global cognitive function
Time frame: Participants will undergo a 1-week baseline assessment, followed by a 5-week intensive intervention phase. A post-intervention assessment will be conducted at Week 6. Follow-up assessments will be performed at Weeks 10, 14, and 18. The total study durati
Executive Function, Working Memory, Verbal Fluency, Episodic Memory, Planning, and Global Cognition Executive function will be assessed using the Five Digits Test (time/errors; lower = better; no fixed range). Verbal working memory will be measured with Digit Span (approx. 0-16 forward, 0-14 backward; higher = better) and visuospatial working memory with the Corsi Block-Tapping Test (span 2-9; higher = better). Verbal fluency will be assessed using phonemic fluency (letter F; no fixed range; higher = better). Episodic memory will be measured with the Hopkins Verbal Learning Test-Revised (HVLT-R; immediate recall 0-36, delayed recall 0-12; higher = better). Planning ability will be evaluated with the Tower of London (moves/time; lower = better; no fixed range). Global cognition will be assessed using the Montreal Cognitive Assessment (MoCA; 0-30; higher = better). [Time Frame: Baseline, Week 5, Week 8, and Week 12]
1 secondary outcome
Calcium-related molecular biomarkers (STIM and ORAI gene expression)
Time frame: Baseline (pre-intervention), post-intervention (after completion of the intensive phase, Week 5), and follow-up assessments (Weeks 8 and 12)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2026.
- Background: PubMed 27145765Dedoncker J, Brunoni AR, Baeken C, Vanderhasselt MA. The effect of the interval-between-sessions on prefrontal transcranial direct current stimulation (tDCS) on cognitive outcomes: a systematic review and meta-analysis. J Neural Transm (Vienna). 2016 Oct;123(10):1159-72. doi: 10.1007/s00702-016-1558-x. Epub 2016 May 4.
- Background: PubMed 30503376Galli G, Vadillo MA, Sirota M, Feurra M, Medvedeva A. A systematic review and meta-analysis of the effects of transcranial direct current stimulation (tDCS) on episodic memory. Brain Stimul. 2019 Mar-Apr;12(2):231-241. doi: 10.1016/j.brs.2018.11.008. Epub 2018 Nov 17.
- Background: PubMed 31782505Huo L, Zhu X, Zheng Z, Ma J, Ma Z, Gui W, Li J. Effects of Transcranial Direct Current Stimulation on Episodic Memory in Older Adults: A Meta-analysis. J Gerontol B Psychol Sci Soc Sci. 2021 Mar 14;76(4):692-702. doi: 10.1093/geronb/gbz130.
- Background: PubMed 30395314Manenti R, Sandrini M, Gobbi E, Binetti G, Cotelli M. Effects of Transcranial Direct Current Stimulation on Episodic Memory in Amnestic Mild Cognitive Impairment: A Pilot Study. J Gerontol B Psychol Sci Soc Sci. 2020 Aug 13;75(7):1403-1413. doi: 10.1093/geronb/gby134.
- Individual participant dataSharing planned: Undecided. This study represents the first time the research team has registered a clinical trial; therefore, the process of defining and classifying outcome measures has been carried out with particular care to ensure methodological clarity and coherence. In addition to clinical and neuropsychological outcomes, the study includes an exploratory measurement of molecular biomarkers related to calcium (Ca²⁺) homeostasis, as age-related changes disrupt multiple electrophysiological processes, particularly at the hippocampal level. These alterations have been proposed as potential biomarkers of cognitive decline. The inclusion of this measurement is complementary and exploratory in nature, and its purpose is to provide additional information that allows for a more comprehensive interpretation of the cognitive changes observed following transcranial direct current stimulation (tDCS). The collection of biological samples through buccal swabbing constitutes a non-invasive, safe, and appropriate proced
Related trials for Cognitive Dysfunction ( MMSE < 24 )
Not yet recruiting
Animal-Assisted Therapy Combined With Standard Rehabilitation for Motor Recovery in Dementia Patients in a Medical and Rehabilitation Care Unit
Dementia, Cognitive Dysfunction ( MMSE < 24 )
Recruiting
The Effects of Virtual Reality-based Training for the Treatment of Neglect Syndrome in Stroke: a Randomized Controlled Trial
Stroke ( 3 Months After Onset), Cognitive Dysfunction ( MMSE < 24 )
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transcranial Direct Current Stimulation in people with Cognitive Dysfunction ( MMSE < 24 ), run by Universidad Autónoma del Estado de Hidalgo at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 15 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Global cognitive function (time frame: Participants will undergo a 1-week baseline assessment, followed by a 5-week intensive intervention phase. A post-intervention assessment will be conducted at Week 6. Follow-up assessments will be performed at Weeks 10, 14, and 18. The total study durati). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07531888, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2026.